Overview A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease Status: Recruiting Trial end date: 2025-02-06 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety of Guselkumab in participants with Crohn's disease. Phase: Phase 3 Details Lead Sponsor: Janssen Pharmaceutical K.K.